Arch Therapeutics Inc
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and… Read more
Market Cap & Net Worth: Arch Therapeutics Inc (ARTH)
Arch Therapeutics Inc (OTCQB:ARTH) has a market capitalization of $955.54K ($955.54K) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #36233 globally and #11783 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arch Therapeutics Inc's stock price $0.22 by its total outstanding shares 4444360 (4.44 Million).
Arch Therapeutics Inc Market Cap History: 2015 to 2025
Arch Therapeutics Inc's market capitalization history from 2015 to 2025. Data shows change from $179.55 Million to $955.54K (-44.30% CAGR).
Arch Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arch Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
424.93x
Arch Therapeutics Inc's market cap is 424.93 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $84.44 Million | $11.56K | -$6.24 Million | 7301.59x | N/A |
| 2022 | $23.11 Million | $15.65K | -$5.28 Million | 1476.53x | N/A |
| 2023 | $32.18 Million | $75.72K | -$6.98 Million | 424.93x | N/A |
Competitor Companies of ARTH by Market Capitalization
Companies near Arch Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Arch Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Arch Therapeutics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Arch Therapeutics Inc's market cap moved from $179.55 Million to $ 955.54K, with a yearly change of -44.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $955.54K | +0.70% |
| 2024 | $948.87K | -97.05% |
| 2023 | $32.18 Million | +39.23% |
| 2022 | $23.11 Million | -72.63% |
| 2021 | $84.44 Million | -36.62% |
| 2020 | $133.24 Million | -39.94% |
| 2019 | $221.86 Million | -52.91% |
| 2018 | $471.10 Million | +23.27% |
| 2017 | $382.17 Million | -26.32% |
| 2016 | $518.66 Million | +188.86% |
| 2015 | $179.55 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Arch Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $955.54K USD |
| MoneyControl | $955.54K USD |
| MarketWatch | $955.54K USD |
| marketcap.company | $955.54K USD |
| Reuters | $955.54K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.